GemVax "Alzheimer's Treatment Candidate Shows Significant Improvement in Clinical Trials... Phase 3 Underway"
[Asia Economy Reporter Choi Dae-yeol] GemVax announced on the 20th that the results of the domestic Phase 2 clinical trial of its candidate drug being developed for the treatment of Alzheimer's disease showed "significant improvement related to the primary efficacy variable," and added, "Further research indicates a high possibility of controlling disease progression and alleviating symptoms in patients with moderate to severe Alzheimer's disease." The company also stated that it will proceed with the domestic Phase 3 trial as well as overseas clinical trials and expansion of indications.
Hot Picks Today
Cerebras Soars 70% on IPO Debut: Is Nvidia's Reign Ending as a New AI Semiconductor Power Emerges?
- "Neither Black Hole nor Neutron Star"... Korean Researchers Suggest Possibility of a 'Third Ultra-Dense Celestial Body' [Reading Science]
- "Multi-Million Won Bonuses, Life Is Sweet"—Even Employee Reactions... SK hynix Overtakes Samsung to Claim No. 1 Spot
- "It Costs 100,000 Won for Two Hours"...No Place for Kids to Play if Parents Can't Afford It
- Japanese Teacher Dismissed for Obscene Acts Involving Third-Grade Girl's Water Bottle
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
